New results on METAglut1™ validation study presented at the meeting of SFNP 2020
January 15, 2020
Introducing METAflow our innovative AI cytometry data analysis platform at ESCCA 2022
September 21, 2022
February 2-4, 2022.
[EVENTS] Company ; METAglut1™
We are thrilled to share our experience at the 31st Congress of the Société Française de Neurologie Pédiatrique (SFNP), where we had the opportunity to present a poster detailing the results of our validation study for METAglut1™.
METAglut1™ is our first IVD blood test to aid the early diagnosis of Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, a rare metabolic disorder that can significantly impact the lives of affected children.
The congress of the SFNP (Société Française de Neurologie Pédiatrique) is a prominent congress dedicated to pediatric neurology, bringing together healthcare professionals, researchers, and experts in the field.
This annual event serves as a platform for discussing the latest advancements, sharing research findings, and fostering collaboration among specialists.
Participating in the SFNP 2022 has invigorated our commitment to advancing research and innovation in pediatric health. We are dedicated to collaborating with experts and stakeholders to improve patient outcomes and have the test as fast as possible covered and available.
